Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts: Gene/Protein Disease Symptom Drug Enzyme Compound   Target Concepts: Gene/Protein Disease Symptom Drug Enzyme Compound

---

Query: CAS:6893-26-1 (glutamate)
73,096 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Glutamic acid is the major excitatory amino acid of the central nervous system which interacts with two receptor families, the ionotropic and metabotropic glutamate receptors. The metabotropic glutamate receptors (mGluRs) are coupled to G proteins and can be divided into three subgroups based on their sequence homology, signal transduction pathway and pharmacology. In this study, we describe the cloning of the cDNA encoding the human metabotropic glutamate receptor type 3 (HmGluR3). It was obtained by reverse transcription-polymerase chain reaction (RT-PCR) with degenerate oligonucleotides corresponding to highly conserved sequences between rat mGluRs. The receptor shows 879 amino acids with 96% amino acid sequence identity with rat mGluR3. It is strongly expressed in fetal and adult whole brain, especially in caudate nucleus and corpus callosum. The gene was identified by fluorescence in situ hybridization on chromosome 7 band q22. Activation of the human mGluR3, permanently expressed in Baby Hamster Kidney (BHK) cells, by excitatory amino acid inhibits the forskolin-stimulated accumulation of intracellular cAMP. The rank order of potency is L-glutamic acid > or = (1S,3R)-1-aminocyclopentane-1,3-dicarboxylic acid (1S,3R)-ACPD) >> ibotenic acid > quisqualic acid. (RS)-alpha-methyl-4-carboxyphenylglycine [(RS)-MCPG, 1 mM] is without effect on inhibition of forskolin-induced cAMP accumulation by L-glutamic acid.
...
PMID:Molecular cloning, functional expression, pharmacological characterization and chromosomal localization of the human metabotropic glutamate receptor type 3. 888 60

Glutamic acid activates ionotropic glutamate receptors that mediate excitatory transmission in the central nervous system. The introduction of a methyl group at position 4 of glutamic acid imparts selectivity for kainate receptors, relative to other (N-methyl-D-aspartate and alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) ionotropic glutamate receptors. Among the stereoisomers of 4-methylglutamic acid, the potency of the (2S,4R)-isomer (SYM 2081) to inhibit [3H]kainic acid binding to both wild-type (rat forebrain) and recombinant (GluR6) kainate receptors (IC50 values of approximately 32 and 19 nM, respectively) was comparable to that of kainic acid (IC50 values of approximately 13 and 28 nM, respectively). SYM 2081 was approximately 800- and 200-fold less potent as an inhibitor of radioligand binding to wild-type (rat forebrain) alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid and N-methyl-D-aspartate receptors, respectively. Preexposure of human embryonic kidney 293 cells stably expressing GluR6 receptors to low concentrations of SYM 2081 (30-300 nM) resulted in a reversible blockade of the rapidly desensitizing currents produced by kainate application. At higher concentrations, SYM 2081 (EC50 of approximately 1 microM) elicited kainate-like, rapidly desensitizing, inward currents. Pretreatment of recombinant GluR6 receptors with concanavalin A both abolished the effect of SYM 2081 to block kainate-induced currents and revealed nondesensitizing currents induced by SYM 2081 alone. The latter observations provide strong support for the hypothesis that SYM 2081 blocks kainate-induced currents through a process of agonist-induced desensitization. SYM 2081 also activated alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor currents in primary cultures of cerebral cortex and, consistent with data obtained by radioligand binding, was approximately 5-fold less potent than kainate (EC50 values of 325 and 70 microM, respectively) in this measure. SYM 2081 is a high-affinity, selective, kainate agonist that may prove useful both as a probe to examine the physiological functions of kainate receptors and as the prototype of a novel class of therapeutic agents.
...
PMID:(2S,4R)-4-methylglutamic acid (SYM 2081): a selective, high-affinity ligand for kainate receptors. 899 24

Glutamic acid is an important excitatory neurotransmitter in the mammalian CNS. It has been established that synaptic transmission is mediated mostly by the ionotropic glutamate receptors AMPA and NMDA, with fast and slow kinetics, respectively. The recent demonstration in hippocampal neurones of a class of glutamate receptors that are activated by kainate and not by AMPA (that is, kainate-selective receptors) opens the possibility that receptors, others than those of the AMPA type, might also be involved in fast neurotransmission. The lack of specific pharmacological tools to dissect out AMPA from kainate receptors has hampered the functional study of kainate receptors. However, the recent finding that a 2,3-benzodiazepine (GYK153655) behaves as a selective antagonist of AMPA receptors allows us to address the question of the role of rapidly inactivating kainate receptors in synaptic transmission.
...
PMID:Glutamate receptors of the kainate type and synaptic transmission. 900 11

Glutamic acid is known to be a major excitatory transmitter in the central nervous system. The nature of its receptors on the spinal motoneuron have been well investigated and elucidated to consist of ionotropic (iGluR) as well as metabotropic glutamate receptors (mGluR). However, the role of mGluR on trigeminal motoneurons (TMN) and trigeminal sensory neurons (TSN), which play important roles in mastication, has not been well investigated. In this study, the nature of mGluR on TMN and TSN was investigated using isolated brainstem preparations from neonatal rats. The activities of TMN and TSN were recorded from the trigeminal motor and sensory roots respectively, using a suction electrode. All iGluR agonists depolarized TMN and TSN. The mGluR agonists used were RS-3,5dihydroxyphenylglycine (RS-DHPG) for group I, (2S, 1'R, 2'R, 3'R)-2-(2, 3-Dicarboxycyclopropyl) glycine (DCG-IV) for group II, and L(+)-2-amino-4-phosphono-propinate (L-AP4) for group III. Whereas group I agonist increased spontaneous firing, groups II and III agonists decreased it. Group I agonist depolarized TMN and TSN directly. In contrast, group II and III agonists hyperpolarized TSN but induced no potencial changes in TMN. These results suggested that mGluR exist on TMN and TSN.
...
PMID:[Pharmacological study on metabotropic glutamate receptors on trigeminal neurons]. 971 Oct 41

Amphipholis squamata is a polychromatic luminescent ophiuroid. The effects of amino acids ( &ggr; -aminobutyric acid, GABA, taurine, glycine and glutamate), N-methyl-d-aspartate (NMDA) and the invertebrate neuropeptides Antho-RFamide, FMRFamide and SALMFamides S1 and S2 were tested on acetylcholine-induced luminescence from isolated arms of clear and black specimens of Amphipholis squamata. The results showed that GABA, glycine and Antho-RFamide inhibited ACh-induced luminescence of clear specimens and had no significant effect on black specimens. Glutamic acid had no significant effect on ACh-induced luminescence, but triggered luminescence in the absence of ACh in both types of specimen. Taurine, NMDA and FMRFamide showed no significant effects on either clear or black specimens. S1 potentiated ACh-induced luminescence of clear and black specimens, while S2 had no clear modulatory effect on luminescence. These results suggest that, in addition to the previously described cholinergic system in Amphipholis squamata, there is also a modulatory component to luminescence control. Moreover, we observed a difference in modulation of luminescence between clear and black specimens.
...
PMID:Modulatory effects of some amino acids and neuropeptides on luminescence in the brittlestar amphipholis squamata 1035 81

Glutamic acid represents the most abundant stimulatory neurotransmitter in the central nervous system. Monosodium glutamate (MSG), subcutaneously administered to newborn rats in the perinatal period, induces lesions in 80 to 90% of the neurocytes of arcuate nuclei in the hypothalamus. These nuclei are the site of production of numerous stimulatory and inhibitory hormones including growth hormone releasing hormone (GHRH). The present studies were performed on male Wistar strain rats, subcutaneously injected on days 2, 4, 6, 8, and 10 of postnatal life with MSG at a dose of 4 mg/g body weight. Eighteen-month-old rats were additionally treated with Ambinon. When the animals reached the ages of 6 or 12 months, their body weight, body length and weight of pituitary were determined. On paraffin sections, using immunohistochemical techniques, TSH-immunoreactive cells were detected and characterised by computerised image analysis. The results were subjected to statistical analysis using Student's t test. The rats which were perinatally treated with MSG and examined after 6 or 12 months of life were obese and shorter than control rats by 7% and 10% respectively. They also exhibited a reduction in the weight of the pituitary of 30% and 40% respectively in the two age groups. The proportion of TSH-immunoreactive cells in the pituitary remained unchanged and amounted to 4.5% in the 6-month-old and 5.4% in the 12-month-old rats, respectively. The number of TSH-positive cells per mm2 area remained unchanged. The area and circumference of the cells in the 12-month-old rats were reduced by 22% and 18%, respectively. Perinatal injury to hypophyseal arcuate nuclei induced by monosodium glutamate injection, was not associated with any significant alterations in pituitary structure, as defined by the proportion of pituitary volume occupied by TSH-immunoreactive cells.
...
PMID:Neonatal treatment with monosodium glutamate (MSG): structure of the TSH-immunoreactive pituitary cells. 1080 59

Glutamic acid is the major excitatory neurotransmitter in the mammalian central nervous system (CNS). Specific receptors bind glutamate and some of these when activated open an integral ion channel and are thus known as ionotropic receptors. Within the ionotropic family of glutamate receptors, three major subtypes have been identified using classical specific agonist activation, selective competitive antagonists together with their structural heterogeneity. These receptors have thus been named N-methyl-D-aspartate (NMDA), alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA) and kainate receptors. The NMDA receptor has sites in addition to its agonist-binding site and these seem to either positively or negatively modulate the agonist effect. The NMDA receptor also is unique in that another amino acid, glycine, acts as a co-agonist with glutamate. Changes in glutamate transmission have been associated with a number of CNS pathologies; these include, acute stroke, chronic neurodegeneration, chronic pain, depression, drug dependency, epilepsy, Parkinson's Disease and schizophrenia.
...
PMID:Excitatory amino acid agonists and antagonists: pharmacology and therapeutic applications. 1081 62

Glutamic acid, an excitatory amino acid, has been proposed to play a major deleterious influence in cerebral ischemia. However, the neuroprotective activity of various glutamate receptor antagonists is often low or absent, according to the animal model used. In the present study, we examined the effect of several antagonists acting on glutamate receptors of the N-methyl-D-aspartate (NMDA) type in rats submitted to a brief (5 minutes) global cerebral ischemia. The different compounds used were poorly active or inactive on behavioural and histologic alterations induced by ischemia. Our results suggest that, in this model, overactivation of NMDA receptor complex does not play a predominant role in the pathogenesis of ischemic brain damage.
...
PMID:[Inefficacy of N-methyl-D-aspartate receptor complex antagonists on behavioral and histologic consequences of global cerebral ischemia in rats]. 1091 75

A general method for formulating complex thermodynamic systems in terms of hierarchical interactions has been developed, and has been applied in a previous analyses to the theoretical analysis of cooperativity in a dimeric protein, to the statistical analysis of hemoglobin oxygen binding data, and to the protonation equilibria of inorganic polyprotic acids. Organic polyprotic acids have served as a demonstration system for the development of concepts and methods for treating complex biochemical equilibria. Glutamic acid is the classic test case for understanding proton-proton interactions in organic polyprotic acids, and this system is analyzed using the concept of hierarchical interactions. Second order interactions were apparent between all three possible proton interactions, as has been established previously. The third order interaction between the three protons was found to be insignificant, indicating that protonation of one site on glutamate has no effect on the interaction between the other two protonation sites. This further reinforces the premise that higher order terms, representing more complex interactions, are less likely to be significant than lower order terms. To allow correlation of the interaction values from glutamate with other organic acids, pairwise interaction values between protonation events were then calculated from known pKd values for a number of diprotic acids and bases. For simple straight chain acids and bases a linear log-log relationship was apparent between the number of intervening atoms between the protons and the pK(d,hh) (pKd of interaction). This relationship extended from three atoms (carbonate) up to 11 atoms (azelaic acid) and applied to both dicarboxylic acids and diamine bases. The pairwise interactions in glutamate also followed this simple relationship.
...
PMID:Application of hierarchical thermodynamic interactions to the protonation equilibria of organic polyprotic acids. 1115 69

Glutamic acid is an important excitatory neurotransmitter of the brain. Two key goals of brain amino acid handling are to maintain a very low intrasynaptic concentration of glutamic acid and also to provide the system with precursors from which to synthesize glutamate. The intrasynaptic glutamate level must be kept low to maximize the signal-to-noise ratio upon the release of glutamate from nerve terminals and to minimize the risk of excitotoxicity consequent to excessive glutamatergic stimulation of susceptible neurons. The brain must also provide neurons with a constant supply of glutamate, which both neurons and glia robustly oxidize. The branched-chain amino acids (BCAAs), particularly leucine, play an important role in this regard. Leucine enters the brain from the blood more rapidly than any other amino acid. Astrocytes, which are in close approximation to brain capillaries, probably are the initial site of metabolism of leucine. A mitochondrial branched-chain aminotransferase is very active in these cells. Indeed, from 30 to 50% of all alpha-amino groups of brain glutamate and glutamine are derived from leucine alone. Astrocytes release the cognate ketoacid [alpha-ketoisocaproate (KIC)] to neurons, which have a cytosolic branched-chain aminotransferase that reaminates the KIC to leucine, in the process consuming glutamate and providing a mechanism for the "buffering" of glutamate if concentrations become excessive. In maple syrup urine disease, or a congenital deficiency of branched-chain ketoacid dehydrogenase, the brain concentration of KIC and other branched-chain ketoacids can increase 10- to 20-fold. This leads to a depletion of glutamate and a consequent reduction in the concentration of brain glutamine, aspartate, alanine, and other amino acids. The result is a compromise of energy metabolism because of a failure of the malate-aspartate shuttle and a diminished rate of protein synthesis.
...
PMID:Brain amino acid requirements and toxicity: the example of leucine. 1593 Apr 65


<< Previous 1 2 3 4 5 6 7 8 Next >>

---